The combination of the anticancer drugs bleomycin, etoposide, and cisplatin is the standard therapy for treating ovarian stromal tumors. However, this trio of chemotherapy drugs causes significant side effects and is associated with a high rate of cancer recurrence. Doctors are therefore seeking more effective, less toxic therapies.
In this Gynecologic Oncology Group study, researchers are comparing treatment with paclitaxel and carboplatin to the standard therapy. Patients will be randomly assigned to receive paclitaxel/carboplatin or bleomycin/etoposide/cisplatin. All of these drugs are given intravenously (by vein).
As part of this study, investigators will also be assessing the usefulness of measuring blood levels of a protein called inhibin to determine how well a patient is responding to treatment.